Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific

– Plenary session oral presentation: Monday, April 17, 2023 , 10:15 a.m.-12:15 p.m. ET – Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023 , 1:30-5:30 p.m. ET – Investor call on Monday, April 17, 2023 at 6:30 p.m.

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023  – Based on the Company’s current operating

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief

As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Petosemtamab clinical update planned for first half of 2023 MCLA-129 clinical update planned for second half of 2023 Based on the Company’s current

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned for second half of 2023 - Based on the Company’s